A Genetic Signal, Not a Verdict, on GLP-1 Drugs and Hair Loss

A new paper published online September 3, 2026 in the Journal of Investigative Dermatology, led by Ravi Ramessur and colleagues including Lynn Petukhova, reports that genetically predicted expression of GLP1R, the gene encoding the receptor targeted by drugs like Ozempic and Wegovy, is associated with increased risk of male pattern hair loss (MPHL). The authors used a two-sample Mendelian randomization design, a genetic epidemiology method that leans on naturally occurring variants to approximate what a randomized trial might show without actually running one.

According to a summary from Medscape, the researchers built their genetic instrument from 22 independent cis-expression quantitative trait loci in whole blood, all reaching genome-wide significance, with an F-statistic of 53, a number that speaks to the instrument's statistical strength rather than to how GLP1R behaves in scalp tissue itself. The inverse-variance weighted result showed an odds ratio of 1.07 for MPHL per unit increase in genetically predicted GLP1R expression, a small effect size that nonetheless reached significance across a large population-level dataset.

The study's own supplementary figures narrow the biological picture further. Figure 1 in the paper shows GLP1R expression measured in CD34+ hair follicle progenitor cells from patients with MPHL, drawn from two small RNA sequencing studies, and in body-site expression data from a single research participant catalogued under GSE189684. That is a sample size fit for hypothesis generation, not for characterizing how the receptor functions across scalp biology broadly.

The researchers also ran a multivariable Mendelian randomization analysis adjusting for waist-to-hip ratio adjusted for BMI, systolic blood pressure, serum IGF-1, and testosterone, according to Medscape's account of the paper, a step meant to test whether the GLP1R signal survives once known metabolic and hormonal confounders are accounted for. The design choice reflects an acknowledgment baked into the study itself: GLP1R expression does not operate in isolation from the metabolic pathways that GLP-1 drugs are built to alter in the first place.

A companion ScienceDaily writeup notes a scope limit the authors state directly: because male hair loss has been studied far more extensively than hair loss in women, the researchers were only able to investigate a possible causal pathway in men, leaving female pattern hair loss entirely outside this analysis. That constraint is inherited from the underlying genome-wide association study data the team drew on, not from any assumption about biological sex differences.

Coverage from The Brighter Side of News frames the interpretive boundary plainly, noting Mendelian randomization 'can reduce some forms of confounding that affect ordinary observational studies, but it does not replace a randomized drug trial or prove that a medication causes hair loss.' That distinction matters because the paper's exposure is lifelong genetically predicted receptor expression, not the pharmacological dose and duration of a prescribed GLP-1 receptor agonist, so the study speaks to a biological pathway rather than to what happens when a patient starts an injection this year.

Separately, a real-world TrinetX cohort study published in ScienceDirect and a systematic review posted to PMC have tracked reported hair loss among GLP-1 drug users directly, with the American Academy of Dermatology noting on its public site that dermatologists largely attribute such thinning to the physiological stress of rapid weight loss itself rather than to receptor biology. Those observational reports and this week's genetic analysis approach the same clinical question from different evidentiary footing, and neither one, on its own, closes the gap between a statistical association and a drug label warning.